Bevacizumab/ interferon-alpha2a provides a progression-free survival benefit in all prespecified patient subgroups as first-line treatment of metastatic renal cell carcinoma (AVOREN)

Category Primary study
JournalEuropean Journal of Cancer Supplements, ECCO 14 Meeting Proceedings
Year 2007
This article has no abstract
Epistemonikos ID: 64f862b92db1b76822d214ab89ff430742a56a75
First added on: Jul 09, 2018